Clinical Trials at Ephrata Cancer Center
As of August 2026, 23 paid clinical trials are recruiting at Ephrata Cancer Center, located at 169 MARTIN AVE STE 179, EPHRATA, PA 17522-1724, phone (717) 721-5868 in Ephrata, Pennsylvania. Active studies at this site cover conditions such as Stage IV Lung Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Lung Non-Small Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
23 clinical trials at Ephrata Cancer Center
·Clear filters·Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
E-Mindfulness Approaches for Living After Breast Cancer
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Common conditions studied in Ephrata
- Stage IV Lung Cancer AJCC v8 (5 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (3 active studies)
- Lung Non-Small Cell Carcinoma (3 active studies)
- Recurrent Lung Non-Small Cell Carcinoma (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Ephrata
- NRG Oncology
- SWOG Cancer Research Network
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Wake Forest University Health Sciences
Frequently asked questions
How many paid clinical trials are currently recruiting in Ephrata?
There are approximately 24 recruiting clinical trials in Ephrata, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Ephrata pay participants?
Most recruiting trials in Ephrata compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Ephrata?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Ephrata?
The most common conditions under active study in Ephrata include Stage IV Lung Cancer AJCC v8 (5), Anatomic Stage II Breast Cancer AJCC v8 (3), Lung Non-Small Cell Carcinoma (3), Recurrent Lung Non-Small Cell Carcinoma (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Ephrata?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Ephrata on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Ephrata?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Ephrata?
Recruiting research sites in Ephrata include Ephrata Cancer Center, Ephrata Community Hospital, WellSpan Ephrata Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Ephrata right now?
The largest active categories in Ephrata are Cancer & tumors (23), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Ephrata Cancer Center?
Ephrata Cancer Center is located at 169 MARTIN AVE STE 179, EPHRATA, PA 17522-1724. Use the Google Maps link in the intro above to get directions.
How do I contact Ephrata Cancer Center?
You can reach Ephrata Cancer Center by phone at (717) 721-5868. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.